Topical endotracheal mitomycin C as a complementary treatment for endoscopic treatment of recurrent laryngotracheal stenosis

Miguel, S Cortes de; Barrera, J Cabeza; Medina, Manuel Gallardo; Cádiz, Luis Fernando Cassini Gómez de; Salmerón-García, Antonio; Lucas, F. Rodríguez

doi:10.1016/s2173-5085(11)70006-5

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pledgets of cotton soaked in mitomycin C are topically applied to the areas of stenosis. This is believed to impede the inflammatory response [ 53 ]. However, further research is required before establishing and claiming its efficacy.…”

Section: Current Trends In Managementmentioning

confidence: 99%

Challenges in Endobronchial Tuberculosis: From Diagnosis to Management

Kashyap

Solanki

2014

Pulmonary Medicine

View full text Add to dashboard Cite

Despite the rapid advancement in diagnostic and therapeutic modalities, endobronchial tuberculosis (EBTB), defined as tuberculous infection of the tracheobronchial tree, continues to remain challenging for clinicians. Nonspecific respiratory symptoms along with normal chest radiograph in 10–20% of cases may be alleged for the diagnostic delay. Variable diagnostic yield with sputum microscopy might further compound the problem. In such cases, high resolution computed tomography (HRCT) works as a more sensitive tool and demonstrates involvement of tracheobronchial tree described classically as “tree-in-bud” appearance. Bronchoscopic biopsy is considered the most reliable method for confirmation of the diagnosis with 30% to 84% positivity in different series. Evolution of the disease is also unpredictable with frequent progression to bronchostenosis, therefore requiring regular follow-up and early intervention to halt the natural course. This review article elaborates various aspects of the disease with specific focus on diagnostic dilemma and recent advances in interventional bronchoscopy. In addition, this discussion evokes optimism for further research and introduction of innovative therapeutic modalities.

show abstract

Section: Current Trends In Managementmentioning

confidence: 99%

Challenges in Endobronchial Tuberculosis: From Diagnosis to Management

Kashyap

Solanki

2014

Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

“…Drug-eluting stents may solve the problem of airway restenosis. Paclitaxel [14][15][16] and mitomycin C [17][18][19]-eluting stents have been proven to effectively inhibit fibr006Fblast proliferation in vitro and in animal models, but they also inhibited epithelial cell proliferation [5,[20][21][22][23]. Therefore, to solve restenosis after stenting, a drug that not only inhibits the proliferation of fibroblasts but also has little effect on the epithelialization of the airway needs to be identified.…”

Section: Introductionmentioning

confidence: 99%

The Effects of Rapamycin on the Proliferation, Migration, and Apoptosis of Human Tracheal Fibroblasts (HTrF) and Human Tracheal Epithelial Cells (HTEpiC)

Liu

Zhang

Long

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Restenosis after airway stenting needs to be addressed urgently. Rapamycin has been proven to inhibit restenosis elsewhere. This study aimed at observing its effects on the respiratory tract. Methods: CCK-8, wound healing, Transwell and apoptosis assays were performed to detect the effects of rapamycin on the survival, migration, and apoptosis, respectively, of human tracheal fibroblasts (HTrF) and human tracheal epithelial cells (HTEpiC). Results: The effective concentrations of paclitaxel, mitomycin C and rapamycin on HTrF were 10−7–10−4 mol/L, 10−6–10−4 mol/L, and 10−5–10−4 mol/L, respectively. At the effective concentrations, the inhibition rates of paclitaxel on HTEpiC were (43.03 ± 1.12)%, (49.49 ± 0.86)%, (55.22 ± 1.43)%, and (93.19 ± 0.45)%; the inhibition rates of mitomycin C on HTEpiC were (88.11 ± 0.69)%, (93.82 ± 0.96)%, and (94.94 ± 0.54)%; the inhibition rates of rapamycin on HTEpiC were (10.19 ± 0.35)% and (94.55 ± 0.71)%. At the concentration of (1–4) × 10−5 mol/L, the inhibition rate of rapamycin on HTrF was more than 50%, and that on HTEpiC was less than 20% (p < 0.05). Conclusions: Compared to paclitaxel and mitomycin C, rapamycin had the least effect on HTEpiC while effectively inhibiting HTrF. The optimum concentration range was (1–4) × 10−5 mol/L.

show abstract

“…Mitomycin C has been studied in vivo and clinically for various fibrotic diseases in the airway, such as glottis and subglottic stenosis as well as tracheal and esophageal conditions. 6,7,[10][11][12][13][14] Mitomycin C has been shown to have antifibrotic functions in the airway through the inhibition of fibroblast proliferation and inhibition of their collagen synthesis. [15][16][17][18][19] In the airway literature, mitomycin C has been used in a wide range of doses (range, 0.1-1.0 mg/mL), exposure durations (range, 2-5 minutes), and frequencies (a single dose to 4 reapplications).…”

Section: Introductionmentioning

confidence: 99%

Dose‐dependent effect of mitomycin C on human vocal fold fibroblasts

Chen

Dikkers

et al. 2013

Head & Neck

View full text Add to dashboard Cite

Background The purpose of this study was to evaluate in vitro cytotoxicity and antifibrotic effects of mitomycin C on normal and scarred human vocal fold fibroblasts. Methods Fibroblasts were subjected to mitomycin C treatment at 0.2, 0.5, or 1 mg/mL, or serum control. Cytotoxicity, immunocytochemistry, and Western blot for collagen I/III were performed at days 0, 1, 3, and 5. Results Significant decreases in live cells were measured for mitomycin C-treated cells on days 3 and 5 for all doses. Extracellular staining of collagen I/III was observed in mitomycin C-treated cells across all doses and times. Extracellular staining suggests apoptosis with necrosis, compromising the integrity of cell membranes and release of cytosolic proteins into the extracellular environment. Western blot indicates inhibition of collagen at all doses except 0.2 mg/mL at day 1. Conclusion A total of 0.2 mg/mL mitomycin C may provide initial and transient stimulation of collagen for necessary repair to damaged tissue without the long-term risk of fibrosis.

show abstract

Topical endotracheal mitomycin C as a complementary treatment for endoscopic treatment of recurrent laryngotracheal stenosis

Cited by 4 publications

References 10 publications

Challenges in Endobronchial Tuberculosis: From Diagnosis to Management

Challenges in Endobronchial Tuberculosis: From Diagnosis to Management

The Effects of Rapamycin on the Proliferation, Migration, and Apoptosis of Human Tracheal Fibroblasts (HTrF) and Human Tracheal Epithelial Cells (HTEpiC)

Dose‐dependent effect of mitomycin C on human vocal fold fibroblasts

Contact Info

Product

Resources

About